A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19

Summary

This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics, safety and antiviral activity of galidesivir in subjects with yellow fever (YF) or COVID-19.

Timeline

Start

2020-04-09

Primary completion

2021-01-31

Completion

2021-04-30

Outcome

Met primary endpoint

Stopped (Business): “Sponsor decision to no longer pursue indications studied in this trial”

release “Part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2” biocryst.com ↗

release “No safety signals were identified, and all three dose levels were equally safe.” biocryst.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Galidesivir	Small molecule	—	Intravenous

Indications